Published in J Int AIDS Soc on May 09, 2017
Dolutegravir Plus Lamivudine Simplified Therapy | NCT03884673
The science of Durban, AIDS 2016. J Int AIDS Soc (2017) 0.75
Towards an ideal antiretroviral regimen for the global HIV epidemic. J Virus Erad (2017) 0.75
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
Adverse effects of antiretroviral therapy. Lancet (2000) 4.84
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med (1995) 3.86
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis (2011) 3.58
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med (2013) 3.05
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis (2013) 2.65
Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. Am J Psychiatry (2009) 2.12
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med (1998) 1.88
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med (2014) 1.75
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV (2015) 1.70
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS (2011) 1.62
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol (2008) 1.45
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr (2014) 1.43
The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther (2004) 1.43
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clin Infect Dis (2015) 1.40
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis (2015) 1.37
Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials (2014) 0.99
Current status and prospects of HIV treatment. Curr Opin Virol (2016) 0.94
Hit me with your best shot: dolutegravir - a space in the next WHO guidelines? AIDS (2015) 0.87
Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know? J Int AIDS Soc (2016) 0.86
Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy. J Int AIDS Soc (2015) 0.84
Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc (2014) 0.80
Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. Lancet HIV (2016) 0.79
No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data. Medicine (Baltimore) (2016) 0.78
Elevated Risk of Suicidal Ideation in HIV-Positive Persons. Depress Res Treat (2015) 0.78
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. J Int AIDS Soc (2014) 0.77